[17 May 2013]
Products Affected - Description
Deferoxamine mesylate injection, Bedford
500 mg vial (NDC 55390-0263-10)
2 gram vial (NDC 55390-0265-01)
Deferoxamine mesylate injection, Teva
500 mg vial (NDC 00555-1132-12) - discontinued
Deferoxamine mesylate injection, Watson
500 mg vial (NDC 00591-3974-04) - discontinued
2 gram vial (NDC 00591-3975-30) - discontinued
Reason for the Shortage
- APP states the shortage is due to increased demand.
- Bedford has deferoxamine on shortage due to manufacturing delays. Bedford anticipates full availability of each presentation the company reintroduces to market.
- Ben Venue voluntarily entered into a consent decree with FDA in late-January 2013 which allows Ben Venue to manufacture over 100 medications as long as they are compliant with the decree. Ben Venue supplies multiple products for Bedford Laboratories, a division of Ben Venue.
Teva discontinued deferoxamine 500 mg vials in late-January, 2013.
- Watson discontinued all deferoxamine presentations.
Available Products
Deferoxamine mesylate injection, APP
500 mg vial (NDC 63323-0597-10)
2 gram vial (NDC 63323-0599-30)
Deferoxamine mesylate injection, Hospira
500 mg vial (NDC 00409-2336-10)
2 gram vial (NDC 00409-2337-25)
Deferoxamine mesylate injection, Teva
2 gram vial (NDC 00555-1131-11)
Desferal injection, Novartis
500 mg vial (NDC 00078-0467-91)
2 gram vial (NDC 00078-0347-51)
Estimated Resupply Dates
Bedford has deferoxamine 500 mg and 2 gram vials on back order and the company cannot estimate a release date.
Related Shortages
Updated
May 17, 2013; March 11, 2013; February 5, 2013; January 7, 2013; December 10, 2012; November 27, 2012; October 22, 2012; September 27, 2012; August 3, 2012; June 5, 2012; April 23, 2012; April 4, 2012; March 20, 2012; March 8, 2012; February 16, 2012; January 25, 2012; December 22, 2011; November 22, 2011; October 27, 2011; September 20, 2011; August 25, 2011; June 30, 2011; June 2, 2011; May 11, 2011; March 17, 2011; January 24, 2011; January 6, 2011; December 3, 2010; November 9, 2010; October 11, 2010; September 28, 2010; September 8, 2010; August 24, 2010; August 20, 2010; August 5, 2010; July 21, 2010; July 2, 1010; June 23, 2010, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins